The firm expects Phase III data for its investigational selective estrogen receptor degrader camizestrant and its CLDN18.2 ADC sonesitatug vedotin this year.
Merck Still Wants to "Grow Through Keytruda," Expects $70B in Revenue From New Programs by Mid-2030s
Two antibody-drug conjugates are among 10 programs that the company expects to fuel its growth, the company said.
How to tell your spouse you want a divorce with clarity, kindness, and respect: a compassionate guide for the hardest ...
The main difference between a W-9 and a 1099 is that you fill out a W-9, while the business or entity that is paying you ...
Biologically, how the GLP-1 is delivered into the body should make little difference: It’s the same peptide, just in a ...
New strains of Typhoid that can resist the strongest available antibiotics have emerged in South Asia, raising concerns over the potential spread of drug-resistant infections.
My wife and I have been together for 12 years and overall have a loving, supportive, and great relationship. The birth of our ...
“Recent scientific studies have shown that one dose of the HPV vaccine is as effective as two doses. The CDC is following the ...
U.S. health officials have made unprecedented changes to childhood vaccine recommendations, alarming pediatricians and other ...
Until the mid-seventies, much of the sex in the United States was regulated not by the theory of consent but by that of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback